1532533-67-7

Usage

Uses

Used in Oncology:
TGR-1202 is used as an anticancer agent for its potential to treat lymphoma and leukemia, which are currently in clinical trials. TGR-1202's mechanism of action involves the selective inhibition of the PI3K delta isoform, a key player in the proliferation and survival of cancer cells. This targeted approach may offer a more precise treatment strategy with fewer side effects compared to non-specific therapies.
Used in Inflammatory Disease Treatment:
TGR-1202 is used as an anti-inflammatory agent due to its role in modulating immune system function. The PI3K delta isoform's involvement in immune response regulation makes TGR-1202 a candidate for treating inflammatory conditions by potentially reducing inflammation through its inhibitory effects on the overactive PI3K delta pathway.
Used in Preclinical Cancer Research:
TGR-1202 is used as a research tool in preclinical studies for a range of other cancers. TGR-1202's demonstrated efficacy in inhibiting the PI3K delta isoform has shown promise in various cancer types, suggesting its potential broad applicability in oncology research and development.

Upstream product

• 1300582-10-8 2-(1-bromoethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 331-25-9 (3-fluorophenyl)acetic acid 
• 202865-80-3 4-bromo-2-fluoro-1-isopropoxybenzene 
• 2105-94-4 4-bromo-2-fluorophenol 
• 1479107-53-3 (R)-2-(1-(benzyloxy)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1408087-64-8 3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1479107-10-2 (R)-6-fluoro-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one 
• 1532533-36-0 (R)-1-(6-fluoro-3-(3-fluorophenyl)-4-oxo-4H-chromen-2-yl)ethyl 4-chlorobenzoate 
• 1532533-34-8 (S)-6-fluoro-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one 
• 1532533-32-6 2-acetyl-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1532533-31-5 6-fluoro-3-(3-fluorophenyl)-2-(1-hydroxyethyl)-4H-chromen-4-one 
• 1300582-08-4 2-ethyl-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1300582-07-3 1-(5-fluoro-2-hydroxyphenyl)-2-(3-fluorophenyl)ethanone 
• 459-60-9 1-fluoro-4-methoxybenzene 

Relevant academic research and scientific papers

Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor

Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders. In particular, the combination can

SELECTIVE PI3K DELTA INHIBITORS

The present invention relates to selective inhibitors of PI3K delta protein kinases having a lH-pyrazolo[3,4-d]pyrimidine ring system, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kin